Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic natural killer cells + cetuximab
- Development stage
- Unknown
- Lead developer
- CHU de Besançon
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intraarterial, Intravenous
01
Overview
This investigational cell-based immunotherapy is a combination treatment developed by the Centre Hospitalier Universitaire de Besançon for the treatment of EGFR-positive metastatic gastrointestinal cancers with liver involvement. The regimen consists of allogeneic (donor-derived) haploidentical natural killer (NK) cells administered via hepatic intraarterial infusion, combined with the anti-EGFR monoclonal antibody cetuximab. The therapeutic strategy relies on the synergistic effect of direct NK cell-mediated cytotoxicity and cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC). To support the persistence and activity of the infused NK cells, the protocol includes a lymphodepleting conditioning regimen of cyclophosphamide and fludarabine, followed by the administration of high-dose interleukin-2 (IL-2).
- Other names
- allogenic natural killer cells-Centre Hospitalier Universitaire de Besancon-gastrointestinal cancer (metastatic)haploidentical natural killer cellsNK cell immunotherapyallogenic immunotherapy based on Natural Killer cells adoptive transfer
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on allogeneic natural killer cells + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic natural killer cells + cetuximab.